ACHIEVE Control demonstrated superiority of Gla-300 vs. standard of care (SOC) BIs (glargine 100 U/mL and detemir), with a significantly greater proportion of insulin-naive T2D pts treated with Gla-300 achieving the composite primary endpoint of individualized HEDIS A1C targets at 6 months without severe and/or symptomatic documented hypoglycemia (blood glucose [BG] ≤70 mg/dL). Here we report outcomes in pts with and without CVD at baseline (BL). Characteristics at BL were generally well balanced between treatments, with a potential difference in GLP-1 receptor agonist use in CVD pts. In pts without CVD, outcomes consistently favored Gla-300 (Table). In CVD pts, composite endpoint attainment at 12 months was similar with Gla-300 and SOC-BI, while avoidance of hypoglycemia, especially serious hypoglycemia (BG <54 mg/dL), showed a trend favoring Gla-300 (Table); changes in A1C from BL to 12 months with Gla-300 and SOC-BI were similar (LS mean difference [95% CI] 0.12% [-0.12 to 0.35]; p=0.34). The results of this analysis are promising and warrant further exploration of the possibility that the more stable action profile of Gla-300 translates to T2D patients with CVD experiencing serious hypoglycemia less often with Gla-300 than first-generation BIs.


J.P. Frias: Advisory Panel; Self; Becton, Dickinson and Company, Eli Lilly and Company, Gilead Sciences, Inc., Sanofi. Consultant; Self; Echosens, Genentech, Inc., Johnson & Johnson Diabetes Institute, Novo Nordisk Inc., Zafgen, Inc. Research Support; Self; AbbVie Inc., Akcea Therapeutics, Allergan, Amgen Inc., AstraZeneca, Bayer US, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cirius Therapeutics, Elcelyx Therapeutics, Inc., Eli Lilly and Company, Enanta Pharmaceuticals, Inc., GENFIT, Intarcia Therapeutics, Inc., Intercept Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Oramed Pharmaceuticals, Pfizer Inc., Sanofi, TaiwanJ Pharmaceuticals Co., Ltd., Theracos, Inc. Speaker’s Bureau; Self; Merck & Co., Inc., Sanofi. P. Evenou: Employee; Self; Sanofi US. D. Dalton: Employee; Self; Sanofi US. K.M. Dungan: Advisory Panel; Self; Eli Lilly and Company, Elsevier, Sanofi-Aventis. Research Support; Self; Eli Lilly and Company, GlaxoSmithKline plc., Novo Nordisk Inc., Sanofi-Aventis, Viacyte. Other Relationship; Self; DKBmed, UpToDate.


Sanofi US

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at